The short answer
Ginkgo leaf products warrant a bleeding precaution with dalteparin, although the exact risk is uncertain. Regulatory guidance recommends medical consultation with anticoagulants; small trials with other treatments have found no added platelet effect.
What this answer covers
Oral Ginkgo biloba leaf extracts or leaf powder with subcutaneous dalteparin sodium; seeds and injected ginkgo combination medicines are outside this scope.
- Supplement or preparation
- Ginkgo biloba
- Medication ingredient
- dalteparin
Regulatory guidance supports a precaution
The European ginkgo monograph says covered preparations may increase bleeding susceptibility and should be reviewed with a doctor during anticoagulant treatment. Dalteparin already carries a bleeding risk, but the monograph does not quantify a dalteparin-specific interaction.
Controlled studies include null findings
A four-week study of EGb761 with aspirin in older adults found no detected added platelet effect or excess bleeding reports. Another small commercial-product study also found no platelet effect. These results limit a universal harm claim but do not establish safety during dalteparin treatment.
Surgery advice is a different timing question
For covered extracts, the monograph gives a precaution to discontinue ginkgo three to four days before surgery. This is a procedure-related plan for the clinical team, not evidence that spacing ginkgo and dalteparin doses by hours prevents an interaction.
Use a product-specific plan
Tell the dalteparin team about the exact supplement before starting or changing it. Report unusual bleeding or bruising promptly; serious bleeding, black stools or vomiting blood needs urgent assessment. Do not change prescribed dalteparin yourself. Discuss planned procedures as well as the exact leaf preparation; do not substitute advice about other anticoagulants or injected ginkgo mixtures.
Evidence and practical considerations
Timing & monitoring
No universal avoidance or protective spacing interval established; individual product and bleeding-risk review is appropriate.
- Exact scope
- Oral Ginkgo biloba leaf extracts or leaf powder with subcutaneous dalteparin sodium; seeds and injected ginkgo combination medicines are outside this scope. with Subcutaneous dalteparin sodium; active ingredient bridge to RxCUI67109 IN. Not UFH or another LMWH.
- Medication form and route
- subcutaneous dalteparin; oral supplement
What remains uncertain
- Source-specific population, preparation and endpoint limits apply; no universal dose or timing rule.
Factors that may matter: Exact preparation; Dose and duration; Kidney function; Other medicines.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients receiving subcutaneous dalteparin sodium.
Bleeding risk can increase with platelet inhibitors and other anticoagulants. Hyperkalemia is listed among postmarketing reports, whose frequency and causal relationship cannot reliably be established.
How this applies: Exact dalteparin sodium injection product and route; no silent transfer of unfractionated-heparin dosing or monitoring rules.
Does not specifically name these supplements. Not unfractionated heparin, another LMWH, an oral anticoagulant or topical therapy.
Source 2: regulatory herbal monograph
ema.europa.eu · Source check Sep 10, 2026
Population: Users of the specified preparation.
Covered leaf preparations may increase bleeding susceptibility; anticoagulant co-use requires consultation. Gives a three-to-four-day presurgical discontinuation precaution for covered extracts.
How this applies: Exact species, preparation, route and measured endpoints govern applicability; other anticoagulants are not silently treated as dalteparin.
Class-level precaution, not an exact dalteparin trial. Presurgical guidance is not proof that separating same-day doses prevents interaction.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Older adults with peripheral arterial disease or cardiovascular risk; platelet-function analyses included 55 participants.
No detected between-group difference in platelet tests; bleeding/bruising reports were infrequent and similar.
How this applies: Exact species, preparation, route and measured endpoints govern applicability; other anticoagulants are not silently treated as dalteparin.
Small sample; different antithrombotic mechanism from dalteparin and no assurance for all products or high-risk patients.
Source 4: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Ten adult volunteers.
No PFA-100 platelet-function effect from any tested herb; aspirin control inhibited function.
How this applies: Exact species, preparation, route and measured endpoints govern applicability; other anticoagulants are not silently treated as dalteparin.
Only ten volunteers and a laboratory platelet test. Not clinical bleeding surveillance in dalteparin recipients; original experimental component used, not the accompanying review.
Research assessment: · Open full citations ↗
Side effects & toxicity
Indirect supplement and anticoagulant precaution, with source-specific null findings and no quantified dalteparin co-use risk.
- Exact scope
- Oral Ginkgo biloba leaf extracts or leaf powder with subcutaneous dalteparin sodium; seeds and injected ginkgo combination medicines are outside this scope. with Subcutaneous dalteparin sodium; active ingredient bridge to RxCUI67109 IN. Not UFH or another LMWH.
- Medication form and route
- subcutaneous dalteparin; oral supplement
What remains uncertain
- Source-specific population, preparation and endpoint limits apply; no universal dose or timing rule.
Factors that may matter: Exact preparation; Dose and duration; Kidney function; Other medicines.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients receiving subcutaneous dalteparin sodium.
Bleeding risk can increase with platelet inhibitors and other anticoagulants. Hyperkalemia is listed among postmarketing reports, whose frequency and causal relationship cannot reliably be established.
How this applies: Exact dalteparin sodium injection product and route; no silent transfer of unfractionated-heparin dosing or monitoring rules.
Does not specifically name these supplements. Not unfractionated heparin, another LMWH, an oral anticoagulant or topical therapy.
Source 2: regulatory herbal monograph
ema.europa.eu · Source check Sep 10, 2026
Population: Users of the specified preparation.
Covered leaf preparations may increase bleeding susceptibility; anticoagulant co-use requires consultation. Gives a three-to-four-day presurgical discontinuation precaution for covered extracts.
How this applies: Exact species, preparation, route and measured endpoints govern applicability; other anticoagulants are not silently treated as dalteparin.
Class-level precaution, not an exact dalteparin trial. Presurgical guidance is not proof that separating same-day doses prevents interaction.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Older adults with peripheral arterial disease or cardiovascular risk; platelet-function analyses included 55 participants.
No detected between-group difference in platelet tests; bleeding/bruising reports were infrequent and similar.
How this applies: Exact species, preparation, route and measured endpoints govern applicability; other anticoagulants are not silently treated as dalteparin.
Small sample; different antithrombotic mechanism from dalteparin and no assurance for all products or high-risk patients.
Source 4: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Ten adult volunteers.
No PFA-100 platelet-function effect from any tested herb; aspirin control inhibited function.
How this applies: Exact species, preparation, route and measured endpoints govern applicability; other anticoagulants are not silently treated as dalteparin.
Only ten volunteers and a laboratory platelet test. Not clinical bleeding surveillance in dalteparin recipients; original experimental component used, not the accompanying review.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact dalteparin article with independently checked product label and explicit limits on indirect supplement evidence. | |
| Research summary published |
Article revision: ceb06f7c7d1afb2c
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.